Can-Fite BioPharma Ltd.
Namodenoson
decompensated liver cirrhosis
Resolved
103days ago
Catalyst readout · Mar 26, 2026
What's at stake
A key catalyst for Namodenoson (decompensated liver cirrhosis) is expected Mar 26, 2026.
Primary source
· SEC 6-K
verified 12h ago
“A patient with advanced HCC, treated with Namodenoson has reached an overall survival of more than 9 years with complete response to treatment.”